SC
ASND icon

Searle & Co’s Ascendis Pharma A/S ASND Stock Holding History

Searle & Co’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,500
Closed -$205K – 172
2024
Q2 		$205K Buy
+1,500
New +$204K 0.05% 174

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Searle & Co's ASND Position: Q3 2024 in Review

Searle & Co sold out of Ascendis Pharma A/S (ASND) in Q3 2024, closing a stake of 1,500 shares — an estimated $205K sold.

Searle & Co first reported a position in ASND in Q2 2024 and held it in 1 quarter. The position peaked at $205K in Q2 2024. 219 funds tracked by Wall St. Rank hold ASND as of Q3 2024.

  • Searle & Co reported no remaining Ascendis Pharma A/S position as of Q3 2024 after selling out during the quarter.
  • Searle & Co sold 1,500 Ascendis Pharma A/S shares in Q3 2024, an estimated $205K.
  • Searle & Co first reported a position in Ascendis Pharma A/S in Q2 2024 and held it in 1 quarter.
  • Searle & Co's Ascendis Pharma A/S position peaked at $205K in Q2 2024.
  • 219 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2024.

Based on Searle & Co's 13F filing for Q3 2024, filed 22 Oct 2024.